RxDoctor Payments Data

Allison Dawson, MD

Internal Medicine · Sheridan, WYNPI 1114589256

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.

$684in general payments, 2019–2025

Across 35 payments — averaging $19.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$137
  • AstraZeneca$135
  • GSK$123
  • Exact Sciences$64
  • Astellas Pharma US Inc$60
  • Inspire Medical Systems, Inc.$37
  • plus $129 from 5 others

What the payments were for

  • Food & beverage$684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$684 in reported general payments places this provider in the 85th percentile of 101 internal medicine providers in Wyoming.

See all internal medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$171,713
Medicare patients
558
Services billed
3,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$43,834
JardianceEmpagliflozin20$19,066
OzempicSemaglutide16$15,214
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,335
Spiriva RespimatTiotropium Bromide13$6,382
Buprenorphine13$3,217
Celecoxib26$2,125
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,209
Omeprazole60$1,173
Albuterol Sulfate HfaAlbuterol Sulfate55$1,124
Estradiol14$1,039
Levothyroxine Sodium96$1,038
Atorvastatin Calcium79$949
Armour ThyroidThyroid,pork14$887
Bupropion XlBupropion Hcl19$820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$20$15,21416 claims
GSKTrelegy Ellipta$123$10,33516 claims
AbbVieArmour Thyroid$25$88714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 101 internal medicine providers in Wyoming.

Other internal medicine in Sheridan

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →